High CD169 expression in lymph node macrophages predicts a favorable clinical course in patients with esophageal cancer. Issue 12 (5th December 2018)

• Record Type: Journal Article
• Authors: Takeya, Hiroto; Shiota, Takuya; Yagi, Taisuke; Ohnishi, Koji; Baba, Yoshifumi; Miyasato, Yuko; Kiyozumi, Yuki; Yoshida, Naoya; Takeya, Motohiro; Baba, Hideo; Komohara, Yoshihiro
• Is Part Of: Pathology international. Volume 68:Issue 12(2018)
• Page Start: 685
• Page End: 693
• Publication Date: 2018-12-05
• Subjects: CD169 -- CD8 -- esophageal cancer -- lymph node -- macrophage; Pathology -- Periodicals; 616.07
• DOI: 10.1111/pin.12736
• Languages: English
• ISSNs: 1320-5463

Abstract

Abstract : Recent findings indicate CD169‐positive lymph node sinus macrophages (LySMs) in the regional lymph nodes (RLNs) play an important role in anti‐cancer immunity. In the present study, we investigated the correlation between CD169 expression in RLNs and clinicopathologic factors. Higher CD169 expression in LySMs was significantly associated with longer cancer‐specific survival (CSS). The density of tumor‐infiltrating lymphocytes (TILs) in the cancer nest and CD169 expression on LySMs were positively associated in patients who underwent pretreatment. As CD169 expression is thought to reflect a high interferon signature in RLNs, we tried to identify immunity‐related genes that are up‐regulated by interferon in macrophages as well as CD169. Indoleamine 2, 3‐dioxygenase (IDO1) was found to be elevated by interferon, and expression of IDO1 was tested using immunohistochemistry. IDO1 expression on LySMs was positively correlated with CD169 expression; however, there was no significant correlation between IDO1 and clinicopathologic factors. These results suggest that high expression of CD169 in LySMs reflects a high potential for anti‐cancer immune responses in esophageal cancer patients and that monitoring CD169 expression would be useful for evaluating the potential of anti‐cancer immune reactions.